摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴-5-甲基吡嗪 | 98006-90-7

中文名称
2-溴-5-甲基吡嗪
中文别名
2-甲基-5-溴吡嗪
英文名称
2-bromo-5-methylpyrazine
英文别名
5-methyl-2-bromopyrazine
2-溴-5-甲基吡嗪化学式
CAS
98006-90-7
化学式
C5H5BrN2
mdl
——
分子量
173.012
InChiKey
OBZRGWKVWAXNKZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    198℃
  • 密度:
    1.596
  • 闪点:
    74℃

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    25.8
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P280,P301+P312,P302+P352,P305+P351+P338
  • 危险性描述:
    H302,H315,H320,H335

SDS

SDS:940a1934bd4aafb612a0609d0ad6de5c
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Bromo-5-methylpyrazine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-5-methylpyrazine
CAS number: 98006-90-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H5BrN2
Molecular weight: 173.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
    [FR] COMPOSÉS POUR LE TRAITEMENT DES INFECTIONS PAR LE VIRUS RESPIRATOIRE SYNCYTIAL
    摘要:
    本发明涉及式(I)的化合物,其盐、异构体或前药,在治疗病毒感染,特别是呼吸道合胞病毒(RSV)感染方面有用。本发明还涉及制备这些化合物和用于制备它们的中间体的方法。
    公开号:
    WO2011094823A1
  • 作为产物:
    描述:
    2-氨基-5-甲基吡嗪氢溴酸 、 sodium nitrite 作用下, 以 为溶剂, 反应 2.5h, 以64%的产率得到2-溴-5-甲基吡嗪
    参考文献:
    名称:
    2-(2-吡啶基)吡嗪和2,2'-联吡嗪衍生物的合成与表征
    摘要:
    报道了使用Stille偶联从溴吡嗪衍生物中方便,高产地制备2-(2-吡啶基)吡嗪衍生物和2,2'-联吡嗪化合物衍生物的方法。给出了化合物的X射线结构,元素分析,1 H,13 C-NMR和质谱数据。
    DOI:
    10.1002/jhet.3479
点击查看最新优质反应信息

文献信息

  • [EN] 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS 2,3-DISUBSTITUÉS DE 1-ACYL-4-AMINO-1,2,3,4-TÉTRAHYDROQUINOLÉINE ET LEUR UTILISATION COMME INHIBITEURS DE BROMODOMAINES
    申请人:GLAXOSMITHKLINE IP NO 2 LTD
    公开号:WO2014140076A1
    公开(公告)日:2014-09-18
    The present invention relates to novel compounds of formula (I), wherein R1 is C1-4alkyl; R2 is C1-4alkyl, C3-7cycloalkyl, -CH2CF3, -CH2OCH3 or heterocyclyl; R3 is C1-4alkyl, -CH2F, -CH2OH or -CH2O(O)CH3; R4 when present is as defined in claim 1; R5 when present is H, halo, hydroxy or C1-6alkoxy; A is -NH-, -O-, -S-, -SO-, -SO2-, -N(C1-4alkyl)- or -NC(O)(CH3)-; V is phenyl, heteroaromatic or pyridone any of which may be optionally substituted by 1, 2 or 3 substituents; W is CH or N; X is C or N; Y is C or N; and Z is CH or N; subject to the proviso that no more than 2 of W, X, Y and Z are N, pharmaceutical compositions containing such compounds and to their use as bromodomain inhibitors.
    本发明涉及式(I)的新化合物,其中R1为C1-4烷基;R2为C1-4烷基、C3-7环烷基、-CH2CF3、-CH2OCH3或杂环烷基;R3为C1-4烷基、-CH2F、-CH2OH或-CH2O(O)CH3;R4存在时如权利要求1所定义;R5存在时为H、卤素、羟基或C1-6烷氧基;A为-NH-、-O-、-S-、-SO-、-SO2-、-N(C1-4烷基)-或-NC(O)(CH3)-;V为苯基、杂芳基或吡啶酮,其中任何一个可以选择性地被1、2或3个取代基取代;W为CH或N;X为C或N;Y为C或N;Z为CH或N;但W、X、Y和Z中不超过2个为N,含有这种化合物的药物组合物以及它们作为溴结构域抑制剂的用途。
  • [EN] METALLO-BETA-LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE MÉTALLO-BÊTA-LACTAMASES
    申请人:MERCK SHARP & DOHME
    公开号:WO2015112441A1
    公开(公告)日:2015-07-30
    The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.
    本发明涉及式(I)的化合物,这些化合物是金属β-内酰胺酶抑制剂,以及这些化合物的合成和与β-内酰胺类抗生素一起用于克服耐药性的用途。
  • [EN] HETEROCYCLIC AMIDES AS KINASE INHIBITORS<br/>[FR] AMIDES HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KINASE
    申请人:GLAXOSMITHKLINE IP DEV LTD
    公开号:WO2016185423A1
    公开(公告)日:2016-11-24
    Disclosed are compounds having the formula: (I) wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    揭示的是具有以下式的化合物:(I) 其中R1、R2和R3如本文所定义,并且制备和使用这些化合物的方法。
  • [EN] PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT<br/>[FR] DÉRIVÉS DE PIPÉRAZINE ET LEUR UTILISATION EN TANT QUE MÉDICAMENT
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2015055698A1
    公开(公告)日:2015-04-23
    The present inventions relate to substituted piperazine derivatives of general formula (I) and to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various medical conditions related to glycine transporter-1 (GlyT1).
    这些发明涉及一般式(I)的取代哌嗪衍生物,以及制备该化合物、包含符合一般式(I)的化合物的药物组合物,以及利用该化合物治疗与甘氨酸转运蛋白-1(GlyT1)相关的各种医疗状况。
  • [EN] 1,4-PYRIDONE COMPOUNDS<br/>[FR] COMPOSÉS 1,4-PYRIDONES
    申请人:EPIZYME INC
    公开号:WO2014100646A1
    公开(公告)日:2014-06-26
    The present invention relates to 1,4-pyridone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    本发明涉及1,4-吡啶酮化合物。本发明还涉及含有这些化合物的药物组合物,以及通过向需要的受试者施用这些化合物和药物组合物来治疗癌症的方法。本发明还涉及利用这些化合物进行研究或其他非治疗目的的用途。
查看更多